Antibodies, protein-based therapeutics, and other biologic modalities are a core part of our pipeline due to their ability to target disease at the molecular level and their versatile applications across therapy areas. By harnessing the power of artificial intelligence (AI) we’re accelerating the discovery and design of these promising molecules.